Bristol Myers Squibb (CELG-RI) Curent Deferred Tax Liability (2009 - 2012)
Bristol Myers Squibb (CELG-RI) reported Curent Deferred Tax Liability of -$10.0 million for Q4 2012, down 66.67% year-over-year from -$30.0 million in Q1 2012, and down 66.67% quarter-over-quarter from -$6.0 million in Q4 2011.
Bristol Myers Squibb (CELG-RI) Curent Deferred Tax Liability (2009 - 2012) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 4 years of Curent Deferred Tax Liability data on file, last reported at -$10.0 million in Q4 2012.
- Curent Deferred Tax Liability for Q4 2012 came in at -$10.0 million, down 66.67% year-over-year; the trailing twelve-month figure through Dec 2012 was -$10.0 million (down 66.67% YoY), and the FY2012 annual result was -$10.0 million, down 66.67% from the prior year.
- Curent Deferred Tax Liability slipped to -$10.0 million in Q4 2012 per CELG-RI's latest filing, from -$6.0 million in the prior quarter.
- Over five years, Curent Deferred Tax Liability peaked at $8.0 million in Q4 2009 and troughed at -$10.0 million in Q4 2012.
- A 4-year average of -$3.2 million and a median of -$5.5 million in 2010 frame the typical range for Curent Deferred Tax Liability.
- The sharpest annual moves came in 2010 and 2011: Curent Deferred Tax Liability plunged 162.5% in 2010, then dropped 20.0% in 2011.
- A 4-year view of Curent Deferred Tax Liability shows it stood at $8.0 million in 2009, then sank by 162.5% to -$5.0 million in 2010, then decreased by 20.0% to -$6.0 million in 2011, then sank by 66.67% to -$10.0 million in 2012.
- Business Quant data shows CELG-RI's Curent Deferred Tax Liability at -$10.0 million in Q4 2012, -$6.0 million in Q4 2011, and -$5.0 million in Q4 2010.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Curent Deferred Tax (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | - |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | - |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | -10.00 Mn |
| Dec 31, 2012 | -10.00 Mn |
| Dec 31, 2011 | -6.00 Mn |
| Dec 31, 2011 | -6.00 Mn |
| Dec 31, 2010 | -5.00 Mn |
| Dec 31, 2010 | -5.00 Mn |
| Dec 31, 2009 | 8.00 Mn |
| Dec 31, 2009 | 8.00 Mn |